SBH
CRL icon

Segall Bryant & Hamill’s Charles River Laboratories CRL Stock Holding History

Segall Bryant & Hamill’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-8,277
Closed -$1.74M – 553
2023
Q2 		$1.74M Sell
8,277
-1,037
-11% -$206K 0.02% 438
2023
Q1 		$1.88M Sell
9,314
-1,859
-17% -$421K 0.02% 430
2022
Q4 		$2.43M Sell
11,173
-13,283
-54% -$2.9M 0.03% 404
2022
Q3 		$4.83M Sell
24,456
-91,888
-79% -$19.8M 0.06% 314
2022
Q2 		$24.9M Sell
116,344
-41,117
-26% -$10M 0.28% 103
2022
Q1 		$44.7M Sell
157,461
-6,298
-4% -$1.94M 0.43% 65
2021
Q4 		$61.7M Sell
163,759
-4,224
-3% -$1.64M 0.57% 43
2021
Q3 		$69.3M Sell
167,983
-1,170
-0.7% -$486K 0.66% 32
2021
Q2 		$62.5M Buy
169,153
+34,241
+25% +$11.4M 0.61% 40
2021
Q1 		$39.1M Buy
134,912
+2,724
+2% +$757K 0.39% 71
2020
Q4 		$33M Buy
132,188
+30,496
+30% +$7.26M 0.37% 77
2020
Q3 		$23M Buy
101,692
+17,600
+21% +$3.65M 0.31% 80
2020
Q2 		$14.7M Buy
+84,092
New +$13.4M 0.25% 99

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Segall Bryant & Hamill's CRL Position: Q3 2023 in Review

Segall Bryant & Hamill sold out of Charles River Laboratories (CRL) in Q3 2023, closing a stake of 8,277 shares — an estimated $1.74M sold.

Segall Bryant & Hamill first reported a position in CRL in Q2 2020 and held it in 13 quarters. The position peaked at $69.3M in Q3 2021. 621 funds tracked by Wall St. Rank hold CRL as of Q3 2023.

  • Segall Bryant & Hamill reported no remaining Charles River Laboratories position as of Q3 2023 after selling out during the quarter.
  • Segall Bryant & Hamill sold 8,277 Charles River Laboratories shares in Q3 2023, an estimated $1.74M.
  • Segall Bryant & Hamill first reported a position in Charles River Laboratories in Q2 2020 and held it in 13 quarters.
  • Segall Bryant & Hamill's Charles River Laboratories position peaked at $69.3M in Q3 2021.
  • 621 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2023.

Based on Segall Bryant & Hamill's 13F filing for Q3 2023, filed 9 Nov 2023.